Literature DB >> 8527005

Does reserpine induce parkinsonian rigidity?

E Lorenc-Koci1, K Ossowska, J Wardas, S Wolfarth.   

Abstract

The aim of the study was to find out whether the reserpine-induced rigidity is similar to that seen in parkinsonism. Simultaneous measurements of the muscle resistance of the hind foot to passive bending and stretching in the ankle joint, as well as of the electromyographic (EMG) activity of the gastrocnemius and tibialis anterior muscles of rats were carried out. Reserpine was injected in a dose of 10 mg/kg alone or with alpha-methyl-p-tyrosine (250 mg/kg) 1, 4 and 27.5 h before the measurements. Reserpine increased the muscle resistance of the rat's hind leg to passive movements. That effect was the strongest at 1-2 h after the injections, and diminished markedly afterwards. The rigidity was accompanied with an increase in the resting, as well as in the stretch-induced short- and long-latency EMG activity in the gastrocnemius muscle. However, the intensity of the latter symptom did not change for a long period of time, which seems to correlate with the striatal dopamine depletion. The results suggest that the reserpine-increased EMG activity is a good model of parkinsonian rigidity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527005     DOI: 10.1007/bf02259662

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  7 in total

1.  The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.

Authors:  M P Hill; J M Brotchie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.

Authors:  Gulnara R Khakimova; Elena A Kozina; Valerian G Kucheryanu; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2016-05-19       Impact factor: 5.590

3.  Effects of sibutramine on the central dopaminergic system in rodents.

Authors:  T Nakagawa; K Ukai; T Ohyama; Y Gomita; H Okamura
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

4.  1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonism-inducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies.

Authors:  Agnieszka Wasik; Irena Romańska; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2009-02-10       Impact factor: 3.911

5.  Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.

Authors:  E Lorenc-Koci; S Wolfarth; K Ossowska
Journal:  Exp Brain Res       Date:  1996-05       Impact factor: 1.972

6.  1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous neurotoxic compound, disturbs the behavioral and biochemical effects of L-DOPA: in vivo and ex vivo studies in the rat.

Authors:  Agnieszka Wąsik; Irena Romańska; Jerzy Michaluk; Małgorzata Kajta; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

Review 7.  Parkinson's disease between internal medicine and neurology.

Authors:  Ilona Csoti; Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.